CymaBay Therapeutics competitors

CymaBay Therapeutics's competitors include MyoKardia, Athersys, Neurocrine Biosciences and Ironwood Pharmaceuticals
Add company...
CymaBay Therapeutics
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases.
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Neurocrine Biosciences
Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Founding Date
Founding Date
1991
Founding Date
2012
Founding Date
1995
Founding Date
1992
Founding Date
N/A
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Newark, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Employees
Employees
21
Employees
1024% increase
Employees
60
Employees
400
Employees
674
Valuation ($)
Valuation ($)
841 m
Valuation ($)
2 b
Valuation ($)
275.9 m
Valuation ($)
9.1 b
Valuation ($)
3 b
Facebook likes
Facebook likes
N/A
Facebook likes
N/A
Facebook likes
475
Facebook likes
N/A
Facebook likes
18
Twitter followers
Twitter followers
N/A
Twitter followers
387
Twitter followers
953
Twitter followers
N/A
Twitter followers
3.1 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Revenue (est.)
$15m (FY, 2016)
Revenue (est.)
$274m (FY, 2016)
Net income
Net income
($27.6m) (FY, 2017)
Net income
($46m) (FY, 2017)
Net income
N/A
Net income
($141.1m) (FY, 2016)
Net income
($81.7m) (FY, 2016)

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A

Funding

Total funding raised
Total funding raised
$ 247.5m
Total funding raised
$ 98m
Total funding raised
$ 9m
Total funding raised
$ 10m
Total funding raised
$ 284m
For sources of this data, please see the company profileDownload Excel

View company profiles

MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
60

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Neurocrine Biosciences
HQ
San Diego, US
Employees
400

Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
674

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company